Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever

Keyphrases

• Active Small Molecules 10%
• Acute Phase 10%
• Age of Infection 10%
• Antiretroviral Therapy 10%
• Arenavirus 10%
• ARGENTINA 10%
• Argentine Hemorrhagic Fever 100%
• Challenge Dose 10%
• Challenge Model 10%
• Clinical Evaluation 10%
• Difficult-to-treat 10%
• Endemic Region 10%
• Etiological Agents 10%
• Favipiravir 100%
• Guinea pig 40%
• Guinea pig Model 100%
• Immune Plasma 10%
• In Vitro Activity 10%
• Influenza 10%
• Intraperitoneal Injection 20%
• Lethal Challenge 10%
• Leukopenia 10%
• New World Arenavirus 10%
• NIAID 10%
• Pharmacokinetic Analysis 10%
• Placebo 20%
• Plasma Parameters 10%
• Post-infection 10%
• Priority Pathogens 10%
• Protection Level 10%
• Ribavirin 10%
• RNA Polymerase Inhibitor 10%
• Small Molecule Antivirals 10%
• T-705 100%
• Thrombocytopenia 10%
• Twice Daily 10%
• Viral Titer 10%
• Virus 40%
• Virus Challenge 10%
• Virus Infection 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiserum 10%
• Antiviral Therapy 10%
• Antivirus Agent 20%
• Argentine Hemorrhagic Fever 100%
• Clinical Trial 10%
• Favipiravir 100%
• Guinea Pig 40%
• Guinea Pig Model 100%
• Infection 20%
• Infectious Agent 10%
• Intraperitoneal Injection 10%
• Leukopenia 10%
• New World Arenavirus 10%
• Pharmacokinetics 10%
• Placebo 20%
• Ribavirin 10%
• RNA Directed RNA Polymerase Inhibitor 10%
• Thrombocytopenia 10%
• Virus Infection 100%